Home
Scholarly Works
Late-breaking abstract: Efficacy and safety of...
Conference

Late-breaking abstract: Efficacy and safety of multiple doses of QGEo31 (ligelizumab) versus omalizumab and placebo in inhibiting the allergen induced early asthmatic response

Authors

Gauvreau GM; Boulet L-P; Leigh R; Cockcroft DW; Davis BE; Mayers I; FitzGerald JM; Dahlen B; Watson RM; Milot J

Volume

44

Publisher

EUROPEAN RESPIRATORY SOC JOURNALS LTD

Publication Date

September 1, 2014

Conference proceedings

EUROPEAN RESPIRATORY JOURNAL

ISSN

0903-1936

Labels

Contact the Experts team